FDA alerts providers to recall of drug to treat serious bacterial infections
The Food and Drug Administration yesterday alerted pharmacy and nursing professionals to a voluntary recall of seven lots of an injectable drug used to treat certain serious bacterial infections, which may contain glass particulate matter. The Teva Pharmaceuticals Amikacin Sulfate Injection USP vials were distributed nationwide through wholesalers, retailers and pharmacies. Anyone with an existing inventory of the recalled lots should stop using and quarantine the product immediately, FDA said. Health care professionals and patients are encouraged to report adverse events or side effects related to the use of the product to the FDA's MedWatch program.
Related News Articles
Chairperson's File
For decades, hospitals and health systems have used innovation to improve patient care and outcomes. We have seen dramatic improvements and know we can never…
Headline
A measles outbreak in Utah is now at 486 cases, with 107 reported in the last three weeks, according to data from the state’s Department of Health and Human…
Headline
The Centers for Disease Control and Prevention March 26 released a report on U.S. child vaccination coverage by age 2. The report found that coverage among…
Headline
The Centers for Disease Control and Prevention announced today that there are now 1,487 confirmed measles cases nationwide so far this year. The CDC said 5% of…
Headline
The Centers for Disease Control and Prevention released a report March 12 on the effectiveness of the flu vaccine for the 2025-2026 flu season, finding that it…
Headline
March 8-14 marks Patient Safety Awareness Week. The AHA has several resources including podcasts, videos and reports that show how AHA members are advancing…